Hemopoietic growth factors and marrow transplantation: an overview

Current clinical trials suggest that use of G-CSF and GM-CSF is likely to benefit marrow transplant patients by significantly reducing the duration of post-transplant leukopenia. It remains to be determined whether the use of megakaryocyte-active growth factors (e.g., Multi-CSF) will prove of value in elevating platelet levels in such patients.